Intelliseq
Klaudia Szklarczyk-Smolana has a diverse work experience. Klaudia is the CEO and co-founder of Intelliseq, a position they have held since February 2022. Prior to that, they served as the co-founder and Business Development Director of Intelliseq from September 2015 to February 2022.
Additionally, Klaudia worked as a Postdoctoral Researcher at Jagiellonian University starting in 2016. Before that, they were a Science Communicator at Adamed SmartUp and Uniwersytet Dzieci from 2014 onwards.
Klaudia Szklarczyk-Smolana completed their education history as follows:
- Klaudia obtained a Doctor of Medical Sciences degree in Medical Biology, Neuropsychopharmacology from the Institute of Pharmacology Polish Academy of Sciences in 2016.
- Klaudia pursued Executive Education at the Massachusetts Institute of Technology from an unspecified start year to 2019.
- Klaudia received Young Investigator Training in Neuroscience from the Universidad Complutense de Madrid in 2012.
- In 2011, they attended the EMBO Neuroscience School at the University of Zurich.
- Klaudia completed a postgraduate program in Neuroscience: From brain research to clinical practice at Uniwersytet SWPS (year unspecified).
- In 2010, they earned a Master of Science (M.Sc.) degree in Applied Psychology from Jagiellonian University.
- Klaudia participated in the Program Mobilności Studenckiej MOST in Psychologia Ekonomiczna at the University of Warsaw in 2009.
This person is not in any teams
This person is not in any offices
Intelliseq
Intelliseq is a genome informatics company developing bioinformatics tools for diagnostics, therapy, and prevention based on genetic data. Currently bioinformatics systems in laboratories are not ready for genomics at scale. The analysis process of already sequenced genomes is now mostly expensive and labor-intensive. In response to this problemthe company created a cloud-based platform called IntelliseqFlow that allows for automated bioinformaticianless generation of result reports that accelerates the entire diagnostic process and reduces the costs that the laboratory had to deal with so far. IntelliseqFlow translates raw DNA data into final reports automatically, making the analysis step fast, simple, cost-effective and user-friendly. Allows users to choose ready-to-use workflows for PGx, Germline Disorders, Somatic Cancer, and Polygenic Risk Scoring all wrapped-up in one user-friendly platform. It comprises AI-based algorithms, easy to operate pipelines, customized workflows, and APIs that make it simple to integrate our engine with laboratory information systems.The company was established in 2014 by a group of scientists fascinated with pharmacogenomics and transcriptomics. Intelliseq’s products are currently being used by laboratories in Asia, Europe, and the US.